Updates are available Correction dated 2026-01-03

Article History

Received: 12 November 2025

Accepted: 12 November 2025

First Online: 3 December 2025

Change Date: 30 December 2025

Change Type: Update

Change Details: The original online version of this article was revised: to correct the article title to "SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2025)"

Change Date: 3 January 2026

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s12094-025-04184-6

Declarations

:

: Maria José Safont Aguilera: fees for attendance at conferences and courses from Amgen, BMS, Merck, Sanofi, Servier, and fees as a speaker or consultant: Amgen, Bayer, BMS, GSK, Merck, Pierre Fabre, Sanofi, Servier, and Takeda. Rosario Vidal Tocino reports speaker and other fees from Servier, BMS and Merck; advisory board from GSK and Bayer; advisory board, speaker and other fees from MSD and Amgen; other fees from Roche and Speaker from Astellas and Pierre Fabre. Vicente Alonso Orduña: fees for advisory board from AMGEN and speaker fees from Novartis, Merck and Servier. Ferrán Losa Gaspá, Encarna González-Flores, María Luisa Limón Mirón, José Luis Manzano Mozo, María del Carmen Riesco Martínez, Elena Asensio Martínez, and Ruth Vera García have nothing to disclose.

: Not applicable. The manuscript does not contain clinical studies or patient data.